Replies to post #687828 on NorthWest Biotherapeutics Inc (NWBO)

[Zadie420]

I may be wrong. But if the data shows efficiency specially when we are dealing with rGBM they can announce it earlier and complete the full analysis later. Remember this trial concerns rGBM with short life of OS.

[skitahoe]

There is a protocol for releasing data that calls for peer review prior to open discussion of the data, often Phase 1 trial data isn't discussed at all. I would suspect that at an appropriate time the data will be discussed, but this trial wasn't sponsored by the company, so they really won't discuss it at all until after it's been presented in such a forum.

I would hope that it's not long before a Phase 2 that's designated as registrational, or Phase 2/3 Trial is initiated with NWBO being one of the trial sponsors.

I don't believe that TLD statements are normally issued for Phase 1 Trials, or by most trials run at research institutions, but Dr. Liau and others speak at many smaller, and larger presentations where discussing the data could be considered as proper peer review for a Phase 1 Trial. It's not impossible for a Phase 1 that's truly dynamic to be presented at a major conference, like ASCO, but it's doubtful this year as the Abstract would need to have been submitted back in February. Perhaps it would fit into one of the conferences closer to year's end.

Gary

[biosectinvestor]

It’s not up to the company. It’s UCLA’s trial. Hopefully they will be fast.